A company focused on developing novel treatments for mental health this week announced that it has submitted an application to the U.S. Food and Drug Administration seeking the approval of ...
Training marks Poland's first International Psychedelic Therapy Training Program, expanding MAPS' global education initiativeProgram demonstrates ...
Abuse allegations and infighting helped kill a campaign to legalize MDMA for medical use. Trumpworld is giving the therapy’s advocates hope for a second shot. This was supposed to be the year of the ...
Numinus is a leading player in the emerging field of psychedelic therapy. This article delves into their groundbreaking work and collaboration with MAPS (Multidisciplinary Association for Psychedelic ...
Dr. Shannon will provide valuable expertise towards MDMA-Assisted Therapy Training from a MAPS clinical protocols foundation. CALGARY, AB, Oct. 24, 2023 /PRNewswire/ - ATMA Journey Centers Inc. ("ATMA ...
Multidisciplinary Association for Psychedelic Studies, or MAPS, said Thursday that it plans to apply for a New Drug Application (NDA) with the U.S. Food and Drug Administration after positive results ...
Results met study pre-specified primary and key secondary endpoints and will support new drug application submission expected in third quarter of 2023 No serious adverse events observed in the MDMA ...
If approved for medical use, the Drug Enforcement Administration would be required to reschedule the drug. MAPS Public Benefit Corporation is seeking approval of its MDMA (midomafetamine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback